Your browser doesn't support javascript.
Discrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs.
Ten Hagen, Nele Alexandra; Twele, Friederike; Meller, Sebastian; Jendrny, Paula; Schulz, Claudia; von Köckritz-Blickwede, Maren; Osterhaus, Ab; Ebbers, Hans; Pink, Isabell; Welte, Tobias; Manns, Michael Peter; Illig, Thomas; Fathi, Anahita; Addo, Marylyn Martina; Nitsche, Andreas; Puyskens, Andreas; Michel, Janine; Krause, Eva; Ehmann, Rosina; von Brunn, Albrecht; Ernst, Christiane; Zwirglmaier, Katrin; Wölfel, Roman; Nau, Alexandra; Philipp, Eva; Engels, Michael; Schalke, Esther; Volk, Holger Andreas.
  • Ten Hagen NA; Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.
  • Twele F; Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.
  • Meller S; Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.
  • Jendrny P; Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.
  • Schulz C; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.
  • von Köckritz-Blickwede M; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.
  • Osterhaus A; Department of Biochemistry, University of Veterinary Medicine Hannover, Hannover, Germany.
  • Ebbers H; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.
  • Pink I; KynoScience Unternehmergesellschaft, Hörstel, Germany.
  • Welte T; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
  • Manns MP; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
  • Illig T; Hannover Medical School, Hannover, Germany.
  • Fathi A; Hannover Unified Biobank, Hannover Medical School, Hannover, Germany.
  • Addo MM; Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
  • Nitsche A; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • Puyskens A; German Center for Infection Research, Hamburg-Lübeck- Borstel-Riems, Hamburg, Germany.
  • Michel J; Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
  • Krause E; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • Ehmann R; German Center for Infection Research, Hamburg-Lübeck- Borstel-Riems, Hamburg, Germany.
  • von Brunn A; Center for Biological Threats and Special Pathogens (ZBS) 1, Highly Pathogenic Viruses, World Health Organisation Reference Laboratory for SARS-CoV-2 and World Health Organisation Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute, Berlin, Germany.
  • Ernst C; Center for Biological Threats and Special Pathogens (ZBS) 1, Highly Pathogenic Viruses, World Health Organisation Reference Laboratory for SARS-CoV-2 and World Health Organisation Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute, Berlin, Germany.
  • Zwirglmaier K; Center for Biological Threats and Special Pathogens (ZBS) 1, Highly Pathogenic Viruses, World Health Organisation Reference Laboratory for SARS-CoV-2 and World Health Organisation Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute, Berlin, Germany.
  • Wölfel R; Center for Biological Threats and Special Pathogens (ZBS) 1, Highly Pathogenic Viruses, World Health Organisation Reference Laboratory for SARS-CoV-2 and World Health Organisation Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute, Berlin, Germany.
  • Nau A; Bundeswehr Institute of Microbiology, Munich, Germany.
  • Philipp E; Max von Pettenkofer-Institute, Virology, Ludwig Maximilian University of Munich, Munich, Germany.
  • Engels M; German Center for Infection Research, Munich, Germany.
  • Schalke E; Bundeswehr Medical Service Headquarters, Koblenz, Germany.
  • Volk HA; Bundeswehr Institute of Microbiology, Munich, Germany.
Front Med (Lausanne) ; 8: 749588, 2021.
Article in English | MEDLINE | ID: covidwho-1556183
ABSTRACT

Background:

Testing of possibly infected individuals remains cornerstone of containing the spread of SARS-CoV-2. Detection dogs could contribute to mass screening. Previous research demonstrated canines' ability to detect SARS-CoV-2-infections but has not investigated if dogs can differentiate between COVID-19 and other virus infections.

Methods:

Twelve dogs were trained to detect SARS-CoV-2 positive samples. Three test scenarios were performed to evaluate their ability to discriminate SARS-CoV-2-infections from viral infections of a different aetiology. Naso- and oropharyngeal swab samples from individuals and samples from cell culture both infected with one of 15 viruses that may cause COVID-19-like symptoms were presented as distractors in a randomised, double-blind study. Dogs were either trained with SARS-CoV-2 positive saliva samples (test scenario I and II) or with supernatant from cell cultures (test scenario III).

Results:

When using swab samples from individuals infected with viruses other than SARS-CoV-2 as distractors (test scenario I), dogs detected swab samples from SARS-CoV-2-infected individuals with a mean diagnostic sensitivity of 73.8% (95% CI 66.0-81.7%) and a specificity of 95.1% (95% CI 92.6-97.7%). In test scenario II and III cell culture supernatant from cells infected with SARS-CoV-2, cells infected with other coronaviruses and non-infected cells were presented. Dogs achieved mean diagnostic sensitivities of 61.2% (95% CI 50.7-71.6%, test scenario II) and 75.8% (95% CI 53.0-98.5%, test scenario III), respectively. The diagnostic specificities were 90.9% (95% CI 87.3-94.6%, test scenario II) and 90.2% (95% CI 81.1-99.4%, test scenario III), respectively.

Conclusion:

In all three test scenarios the mean specificities were above 90% which indicates that dogs can distinguish SARS-CoV-2-infections from other viral infections. However, compared to earlier studies our scent dogs achieved lower diagnostic sensitivities. To deploy COVID-19 detection dogs as a reliable screening method it is therefore mandatory to include a variety of samples from different viral respiratory tract infections in dog training to ensure a successful discrimination process.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Etiology study / Experimental Studies / Randomized controlled trials Language: English Journal: Front Med (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fmed.2021.749588

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Etiology study / Experimental Studies / Randomized controlled trials Language: English Journal: Front Med (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fmed.2021.749588